204 related articles for article (PubMed ID: 9758291)
1. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.
Trémolières F; de Kock F; Pluck N; Daniel R
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):447-53. PubMed ID: 9758291
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group.
O'Doherty B; Daniel R
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):441-6. PubMed ID: 9758290
[TBL] [Abstract][Full Text] [Related]
3. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis.
Léophonte P; Baldwin RJ; Pluck N
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):434-40. PubMed ID: 9758289
[TBL] [Abstract][Full Text] [Related]
4. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.
Aubier M; Verster R; Regamey C; Geslin P; Vercken JB
Clin Infect Dis; 1998 Jun; 26(6):1312-20. PubMed ID: 9636854
[TBL] [Abstract][Full Text] [Related]
5. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
Léophonte P; File T; Feldman C
Respir Med; 2004 Aug; 98(8):708-20. PubMed ID: 15303634
[TBL] [Abstract][Full Text] [Related]
6. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group.
Donahue PE; Smith DL; Yellin AE; Mintz SJ; Bur F; Luke DR
Am J Surg; 1998 Dec; 176(6A Suppl):53S-61S. PubMed ID: 9935258
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute gynecologic infections with trovafloxacin. Trovafloxacin Surgical Group.
Roy S; Koltun W; Chatwani A; Martens MG; Dittrich R; Luke DR
Am J Surg; 1998 Dec; 176(6A Suppl):67S-73S. PubMed ID: 9935260
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.
Pullman J; Champlin J; Vrooman PS
Int J Clin Pract; 2003 Jun; 57(5):377-84. PubMed ID: 12846341
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
O'Doherty B; Dutchman DA; Pettit R; Maroli A
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
[TBL] [Abstract][Full Text] [Related]
10. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
11. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
Sokol WN; Sullivan JG; Acampora MD; Busman TA; Notario GF
Clin Ther; 2002 Apr; 24(4):605-15. PubMed ID: 12017405
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
File TM; Schlemmer B; Garau J; Cupo M; Young C;
J Antimicrob Chemother; 2001 Jul; 48(1):67-74. PubMed ID: 11474633
[TBL] [Abstract][Full Text] [Related]
13. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
15. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.
Hagberg L; Carbon C; van Rensburg DJ; Fogarty C; Dunbar L; Pullman J
Respir Med; 2003 Jun; 97(6):625-33. PubMed ID: 12814146
[TBL] [Abstract][Full Text] [Related]
16. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Petitpretz P; Arvis P; Marel M; Moita J; Urueta J;
Chest; 2001 Jan; 119(1):185-95. PubMed ID: 11157603
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
[TBL] [Abstract][Full Text] [Related]
18. Safety of trovafloxacin in treatment of lower respiratory tract infections.
Williams D; Hopkins S
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):454-8. PubMed ID: 9758292
[TBL] [Abstract][Full Text] [Related]
19. The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Klugman KP
J Antimicrob Chemother; 1996 Jul; 38 Suppl A():133-40. PubMed ID: 8858479
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
Ohno A; Ishii Y; Kobayashi I; Yamaguchi K
J Infect Chemother; 2007 Oct; 13(5):296-301. PubMed ID: 17982717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
